Promis Neurosciences Inc PMN

$3.16 -0.05 (-1.56%)

Valuation

Market cap
28,430,000
Revenue TTM
$0
Net income TTM
$-39,720,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
109,900
Avg volume
198,354
Day's range
$2.99 – $3.35
Shares out
8,997,000
Stochastic %K
14%
Beta
-0.19
Analysts
Strong Buy
Price target
$42.58

Price

Company profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic ol...

Show more

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
416 847 6898
Website
https://www.promisneurosciences.com
Address
1920 Yonge Street, Suite 200, Toronto, Canada

Latest news

Stocktwits

Fruchtworg Nov 21, 12:25 PM
$CAPR might wanna check out $PMN 👀🕵️
0 replies
Fruchtworg Nov 21, 12:12 AM
$CAPR check out $PMN but DYOR ofc
0 replies
Fruchtworg Nov 20, 11:54 PM
$PMN could be checked out by $CAPR investors.. DYOR ofc, opportunity comes and goes
0 replies
Scooter0619 Nov 20, 11:00 PM
$PMN Purchased more stock from 3.10 to 3.00 today. Looking for a holiday trading market next week with an oversold rally in this stock.
0 replies
Biotechgod8797 Nov 20, 9:20 PM
$PMN stock has bounced off $3 a number of times in spite of weak market. expectations are so low that risk:reward is skewed to upside. wouldnt surprise me to see $6 in advance of readout. would only be a 55 million market cap at that level. abos was a rubbish drug. same safety as approved therapies which are poor. pmn has zero aria-e. it clearly targets something different.
0 replies
Pmninvestor Nov 20, 2:41 PM
$PMN i just can’t believe how low volume this stock has ! Because of the results of Acumen is 70% down , without any reason ,they are making huge steps for a small Company ,they are going to Release their own data in the next 2 months , more or less , which are already very good until now ,the management is making the Right choiches, they are Not making promises just to have something to say,and still we are on These Levels ? Market is Sick ,that‘s my best guess. And After the boom,everyone wants a piece of it . Why do you think Dr. Rubino is there for? Really? Make 1+1 . You See ,the result will be M&A! See ya‘ next year !
0 replies
Scooter0619 Nov 20, 4:21 AM
$PMN This is a bear market. Very oversold short term. My take is that if PMN’s results are positive, it won’t matter if the market falls another 30%. The company doesn’t have to raise cash for all of 2027. If they show efficacy on their drug , the stock price will be at least $20. I like the risk reward at current levels. Added more today below $3.15. I will continue to add on any drop in share price, but this is a slow a accumulation. I am comfortable with my position and won’t scream and cry on any negative results.
1 replies
Scooter0619 Nov 20, 1:56 AM
$PMN W.C. Wainwright reiterated their buy on PMN this morning with a buy and $18 target.Google it for full report.
0 replies